BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
1. Completion of Phase 3 SERENITY At-Home clinical trial announced. 2. Topline data readout expected this month for BXCL501. 3. FDA plans to expand IGALMI label for at-home use. 4. Over 200 patients evaluated in a nationwide double-blind trial. 5. No existing FDA-approved treatments for at-home agitation management.